What’s Next? Five Things To Look Out For In June
Alvotech BSUFA Date Arrives Amid Setbacks; Viatris Eylea Trial Kicks Off
Generics Bulletin previews the most notable and anticipated events for June 2023.
You may also be interested in...
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Teva has spoken of its US biosimilars alliance with Alvotech, in the wake of several major setbacks for the companies’ plans to launch a biosimilar to AbbVie’s Humira (adalimumab) juggernaut on 1 July.
As Amneal reported first-quarter results, the firm’s management pointed to a number of specific product opportunities on the horizon as the company seeks to maintain growth momentum.